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Abstract
The Warburg effect describes how cancer cells down-regulate their aerobic respiration and preferentially use glycolysis to
generate energy. To evaluate the link between hypoxia and Warburg effect, we studied mitochondrial electron transport,
angiogenesis and glycolysis in pheochromocytomas induced by germ-line mutations in VHL, RET, NF1 and SDH genes. SDH
and VHL gene mutations have been shown to lead to the activation of hypoxic response, even in normoxic conditions, a
process now referred to as pseudohypoxia. We observed a decrease in electron transport protein expression and activity,
associated with increased angiogenesis in SDH- and VHL-related, pseudohypoxic tumors, while stimulation of glycolysis was
solely observed in VHL tumors. Moreover, microarray analyses revealed that expression of genes involved in these metabolic
pathways is an efficient tool for classification of pheochromocytomas in accordance with the predisposition gene mutated.
Our data suggest an unexpected association between pseudohypoxia and loss of p53, which leads to a distinct Warburg
effect in VHL-related pheochromocytomas.
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Introduction
In 1930, the biochemist Otto Warburg proposed that cancer
was caused by defects in oxidative phosphorylation (OXPHOS) or
aerobic respiration in the mitochondria; this would force the cell to
shift to an anaerobic energy generation process, glycolysis, despite
aerobic conditions [1,2]. After being forgotten for decades, the
Warburg effect is being reconsidered and is now the subject of
increasing interest and analysis [3,4,5]. OXPHOS and glycolysis
have been evaluated in numerous tumor types, including renal
clear cell carcinoma (RCC) in which the majority of glycolytic
enzymes are overexpressed and mitochondrial enzymes under-
expressed relative to patient-matched normal kidney cortex [6].
The Von Hippel-Lindau (VHL) gene is inactivated in 80% of
sporadic RCC, and was thus suspected to mediate this
phenomenon. VHL is a tumor suppressor gene responsible for
the VHL disease, a hereditary neoplastic syndrome characterized
by a predisposition to RCC, retinal and central nervous system
hemangioblastomas, pancreatic cysts and pheochromocytomas
[7]. In vitro studies confirmed that the presence of the VHL protein
was required for intact respiratory chain protein content and
activities in RCC [8,9].
Pheochromocytomas (PH) or functional paragangliomas (fPGL)
are rare catecholamine-secreting tumors arising from the adrenal
medulla or sympathetic nervous ganglia. Approximately 25–30%
of these tumors occur in the context of a hereditary cancer
syndrome [10], one third of which are caused by mutations in the
VHL gene. The other forms are mediated by mutations in the RET
proto-oncogene and the NF1, SDHB, SDHC,o rSDHD tumor
suppressor genes. SDHB, C and D genes encode three of the four
subunits of succinate dehydrogenase (SDH), a mitochondrial
enzyme, which catalyzes the oxidation of succinate into fumarate
in the tricarboxylic acid (TCA) cycle, and feeds electrons to the
ubiquinone pool in the respiratory chain. Identification of
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e7094mutations in SDH genes led to the first and unexpected
demonstration of a tumor suppressor role for a metabolic enzyme
(for review see [11,12]), implicating mitochondrial deficiencies in
tumorigenesis, as first suggested by Otto Warburg 80 years earlier.
Transcription profiling of hereditary and sporadic primary PH/
PGL revealed that tumors associated with VHL [13], and later
SDH [14] mutations display diverse angiogenesis and hypoxia
markers and reduced expression of components of the oxidative
response and TCA cycle. A hypoxia-inducible transcription factor
(HIF)-dependent decrease in SDHB protein expression has also
been described, specifically in SDH- and VHL-related PH/PGL.
A common feature of SDH and VHL mutations is their capacity to
mediate a pseudo-hypoxic response, i.e. the abnormal stabilization of
HIFs under normoxic conditions. The pVHL protein is an E3 ligase
recognition factor, and its key function is the ubiquitination and
subsequent degradation of the a subunit ofHIF-1 and -2 innormoxia
[7]. Inactivation of SDH also leads to HIF stabilization, through the
inhibition of their hydroxylation by prolyl-4-hydroxylases, necessary
for their recognition by pVHL [15,16]. HIFs may be important for
the molecular modulation of the Warburg effect: HIF-1a is a key
regulator of glycolysis and induces the expression of glucose
transporters, glycolytic enzymes and lactate dehydrogenase; it also
mediates the expression of pyruvate dehydrogenase kinase 1, which
inhibits the conversion of pyruvate to acetyl-CoA, thereby attenuat-
ing mitochondrial function and respiration (for review, see [17]).
In this study, we investigated whether there is an increased Warburg
effectinVHL-related PH/PGL,mediated bythe pseudo-hypoxic drive.
We compared angiogenesis, mitochondrial metabolism and glycolysis
in PH/PGL tissues from patients suffering from VHL disease and
patients presenting mutations affecting the SDH, RET or NF1 genes.
Results
Evaluation of HIFs Expression and Angiogenesis in PH/
PGL
First, we performed HIF-1a and HIF-2a immunohistochemistry
to evaluate pseudohypoxia in inherited PH/PGL tissues (Fig. 1A).
We did not detect the expression of either HIF-1a or HIF-2a in
RET and NF1 tumors, although both these proteins were present
in adjacent adrenal tissues (data not shown). A very weak HIF-1a
nuclear labeling was observed in 5 out of 8 SDH-related and in
only 1 out of 10 VHL-related tumors studied. In contrast, HIF-2a
was expressed at a much higher level both in the nucleus and
cytoplasm of tumor cells from all 8 SDH samples and 7 out of 10
VHL PH/PGL. An increase in HIF-2a mRNA expression has
previously been reported in VHL PH/PGL [13]. We thus
compared the expression of both HIFs using genome-wide
expression micro-array in a population of 68 inherited PH/PGL
(28 VHL, 9 NF1, 9 RET, 17 SDHB, 3 SDHD and 2 SDHC)
(Fig. 1B and C). We observed that HIF-2a was indeed
overexpressed in VHL and in SDH-related tumors, as compared
to RET and NF1 ones (4.7 (p=10
26) and 3.5-fold (p=10
25)
increase vs NF1, respectively). There was no difference in HIF-1a
mRNA levels between the different types of tumors studied.
We then used CD34 immunohistochemistry to evaluate the
vascular density in PH/PGL samples (Fig. 2A). Blood vessel
density was 2.5 to 3.5-fold higher in VHL (p,0.05) and in SDH
(p,0.01) related tumors than in RET and NF1-related tumors
(Fig. 2B).
Expression and Activity of the OXPHOS Complexes
We then tested for the Warburg effect in inherited PH/PGL.
We first analyzed the expression and activity of various complexes
of the mitochondrial electron transport system by Western blotting
using a cocktail of monoclonal antibodies optimized for the
detection of one subunit of each of the five OXPHOS complexes
(20 kDa subunit in Complex I, SDHB in Complex II, core 2 in
Complex III, COX II in Complex IV and F1a in ATP synthase).
Each subunit identified was found to be less abundant when the
corresponding complex failed to assemble properly. SDHA
protein was assayed independently in all PH/PGL. Proteins of
complexes I to IV were less abundant in SDH- and VHL-mutated
tumors than in PH/PGL harboring NF1 and RET mutations, but
complex V was relatively similar in all patients (Fig. 3A). Using
Figure 1. Pseudohypoxia in SDH and VHL-related PH/PGL. (A) HIF-1a and HIF-2a immunohistochemistry were performed to evaluate
activation of the hypoxic pathway in all samples. Histogreen was used as a chromogen for detection (blue labeling). Calibration bar: 100 mm.
Microarray evaluation of HIF-1a (B) and HIF-2a (C) expression between SDH, VHL, RET and NF1 tumors. Data are means6SEM. ***p,0.001.
doi:10.1371/journal.pone.0007094.g001
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observation that SDHB protein expression was completely lost
in tumor cells of SDH-related patients and noticeably reduced in
VHL-tumors, while it was still present in vascular endothelial and
smooth muscle cells (Fig. 3B) [18].
Succinate cytochrome c reductase activity (SCCR, complex II +
III) was measured in tumor homogenates: individual SDHB and
SDHA protein expression followed SDH enzymatic activity.
Complex II+III electron transfer activity was abolished in SDH
and substantially lower in VHL samples than in NF1 and RET
tumors (Fig. 3C). The mean values of enzymatic activities revealed
that SCCR activity was 80-fold lower in SDH tumors (p,0.001)
and 4-fold lower in VHL (p,0.01) tumors than in RET and NF1
samples (Fig. 3D). Interestingly, SCCR enzymatic activity as
measured on these frozen tumor tissues was inversely correlated to
the vascularization quantified in the corresponding paraffin-
embedded samples (Fig. 2C). A low complex II activity correlated
with a high vascular density (n=18; r=20.71; p,0.001).
Biochemical studies also revealed that cytochrome c oxidase
(COX, complex IV) activity was approximately 3-fold lower in
SDH (p,0.01) and in VHL (p,0.01) samples than in NF1 and
RET tumors (Fig. 3E). Finally, we assayed quinol cytochrome C
reductase (QCCR, complex III) activity in tumor homogenates.
QCCR activity was also slightly lower in SDH and VHL tumors,
but the difference was much smaller (1.3 and 1.8-fold lower,
respectively, than in NF1 and RET tumors) and was not
statistically significant (Fig. 3F).
Induction of Anaerobic Glycolysis in VHL-related PH/PGL
We then evaluated several aspects of anaerobic glycolysis in
tumor tissues. Activation of the HIF pathway in SDH and VHL
PH/PGL may be responsible for the stimulation of glycolysis and
anaerobic fermentation. Using immunohistochemistry, we studied
the glucose transporter Glut1, a well-described HIF-1a target, but
found that it was restricted to erythrocytes, and was not expressed
in chromaffin cells within PH/PGL tissues (data not shown). We
then assessed the expression of hexokinase-II (HXK-II), another
HIF-1 target, responsible for the first step of glycolysis, i.e. glucose
phosphorylation into glucose-6P. HXK-II is the predominant
hexokinase isoform overexpressed in cancers that exhibit a
Warburg effect [19]. Surprisingly, we observed that HXK-II was
expressed in all VHL samples but was at the threshold of detection
in all RET, NF1 and SDH tumors (Fig. 4A). Likewise, we found
that lactate dehydrogenase (LDH), which catalyses the last step of
anaerobic glycolysis and can be used as an indicator of glycolytic
activity [4], was twice as active in all VHL tumors (p,0.01) than
in NF1 and RET PH/PGL. LDH activity in SDH tissues was
similar to that in RET and NF1 samples (Fig. 4B) and clearly
distinguished VHL from non-VHL PH/PGL (p=0.001).
Microarray Evaluation of Electron Transport and
Glycolysis-Related Genes in Inherited PH/PGL
In order to validate these observations in a larger cohort, we
performed genome-wide expression microarray analysis in a
population of 68 inherited PH/PGL. We compared the expression
profile of genes involved in OXPHOS in 28 VHL tumors with
that of 40 non-VHL PH/PGL (9 NF1, 9 RET, 17 SDHB, 3
SDHD and 2 SDHC). Among the 127 genes studied (200 probe
sets), 47 genes (57 probe sets) were differentially expressed in VHL
samples (Welch’s t-test p,0.01). With the exception of two genes
(COX4I2 and NDUFA4L2), all genes were down-regulated in the
VHL group. The expression profile of these 200 probe sets was
then used to perform a clustering of the 68 tumors (Fig. 5A). Such
an analysis allowed classifying patients into two groups; the first
one included all VHL and SDH patients and the second one
included all RET and NF1 patients Interestingly, the first cluster
could be divided into three subclusters, which separated SDH
tumors in one hand, and VHL PH/PGL in the other hand. The
expression profile of these 200 probe sets was also used to perform
a principal component analysis on the 68 tumors and led to
Figure 2. Angiogenesis in SDH and VHL-related PH/PGL. (A) CD34 immunohistochemistry was performed to evaluate angiogenesis in all
samples. Diaminobenzidin was used as a chromogen for detection (brown labeling). Calibration bar: 200 mm. (B) Quantification of vascular density
showing an increased number of blood vessels in SDH, and VHL tissues. Data are means6SEM. *p,0.05, **p,0.01, ***p,0.001. (C) Correlation
between vascular density and SCCR enzymatic values for individual patients.
doi:10.1371/journal.pone.0007094.g002
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NF1 tumors (Fig. 5B).
Reductions in gene expression detected by microarray analysis
were subtle, and differences never reached a two-fold decrease. In
contrast, the two increased genes were strongly upregulated.
COX4I2 was overexpressed 25- and 45-fold in SDH and VHL
tumors vs NF1, respectively. NDUF4L2 was increased by 11- and
21-fold in SDH and VHL tumors vs NF1, respectively (Fig. 5C).
We performed the same analysis with genes involved in the
glycolytic pathway. Among the 20 genes studied (38 probe sets), 19
genes (37 probe sets) were differentially expressed in VHL samples
(Welch’s t-test p,0.01), including 16 upregulated genes (33 probe
sets) in the VHL group. The expression profile of these 38 probe sets
was used to perform a clustering of the 68 tumors and led to the
division of patients into two clusters (Fig. 6A). The first one regrouped
all non-VHL patients (SDH, NF1 and RET), while all VHL tumors
were included in the second (except one VHL in the first cluster).
Analysis of individual genes revealed a significant up-regulation of
Glut1, Glut3, HXK-II, phosphofructokinase (PFK), enolase 1 (eno1),
phosphoglycerate kinase 1 (PGK1), LDHA, pyruvate dehydrogenase
kinase 1 (PDK1), monocarboxylate transporter 4 (MTC-4), phos-
phoglucomutase 1 (PGM1) in VHL versus non-VHL tissues. The
average overexpression was between 2- to 4-fold, but reached 15- to
17-fold for HXK-II and the lactate transporter MTC-4, respectively.
Interestingly, although SDH patients displayed levels of expression
usually comparable to that observed in RET and NF1 tumors, Glut3,
HXK-II and LDHA were also significantly overexpressed in this
subset of patients (Fig. 6B).
Loss of p53 and TIGAR Expression in VHL-related PH/PGL
Glycolysis was stimulated in all VHL samples but not in SDH
tumors, and it appeared that stimulation of the HIF pathway could
Figure3. Decreased oxidative phosphorylation in SDHandVHL-related PH/PGL. (A)Theabundanceof proteinsof mitochondrial complexesI
(20 kDa subunit), II (SDHB and SDHA), III (Core 2) and IV (Cox II) is lower in PH/PGL from SDH and most VHL than from RET and tumor tissues. (B) SDHB
immunohistochemistry performed on the adrenal adjacent to a RET-related PH and in RET, VHL and SDHD-mutated PH reveals a strong labeling in the
adrenal compared to tumor cells (asterisks). In VHL PH/PGL tumor, expression of SDHB was reduced when compared to RET-related PH while it is absent
in SDHD-related tumor. Note that vascular immunostaining was present in all samples (arrows). Calibration bar: 50 mm. (C) Individual values of SCCR
activity reveal that low complex II+III enzymatic activity is associated with low protein abundance. (D–F) Mean values for mitochondrial complexes II+III,
III and IV reveal a generalized decrease in respiration in SDH and VHL PH/PGL. Data are means6SEM. **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0007094.g003
Warburg Effect in PH/PGL
PLoS ONE | www.plosone.org 4 September 2009 | Volume 4 | Issue 9 | e7094not account for this phenomenon. Recently, the tumor suppressor
p53 was revealed to be a new and unexpected target, stabilized
and activated by pVHL [20]. p53 is a transcription factor that
regulates the expression of TIGAR (TP53-induced glycolysis and
apoptosis regulator), a protein displaying fructose-2,6-bispho-
sphatase activity, thereby lowering fructose-2,6-bisphosphate
concentrations in cells, resulting in inhibition of glycolysis [21].
These findings suggest that anaerobic glycolysis may be stimulated
in cells that lack functional p53. Microarray analysis in the 68
inherited tumors revealed a modest but significant decrease of
TIGAR mRNA expression (0.7 fold, Welch T-test p,0.05) in
VHL vs non-VHL tumors (Fig. 6B).
We thus evaluated the expression of p53 and TIGAR by
immunohistochemistry in 20 available paraffin-embedded speci-
mens (Fig. 7, Table 1). With the exception of 3 patients,
cytoplasmic expression of TIGAR was systematically associated
with the presence of p53 in the nucleus of tumor cells. Patients
could be classified into two groups regarding TIGAR expression.
A positive group displayed a widespread expression of TIGAR,
either throughout the whole tumor sample or heterogeneously,
with positive areas adjacent to TIGAR negative regions. A
negative group showed no TIGAR labeling in tumor cells. The
positive group comprised two NF1, one RET, six SDH and one
VHL tumors. The negative group was composed of seven VHL,
two SDH and one RET tumors. Loss of TIGAR expression thus
appeared preferentially in VHL-related PH/PGL (p=0.025).
Discussion
Here, we show that PH/PGL susceptibility genes influence the
complex cellular balance between angiogenesis, electron transport
and glycolysis, which are regulated by two master genes, HIF and
p53. Our results suggest that activation of the HIF pathway
associated with the loss of p53 activity might mediate the
molecular and biochemical features of the Warburg effect; this
effect was clearly observed in VHL PH/PGL, but not in RET and
NF1 and only partially in SDH tumors.
In accordance with the observations reported by Dahia et al
[14], we observed an overall down-regulation of SDHB protein
level and activity in SDH- and VHL-mutated tissues, but this was
not specific to the SDHB subunit as it was associated with
comparable decreases in SDHA expression and in SDH activity.
Activation of HIFs is a major aspect of cancer biology [22] and has
been associated with the Warburg effect. In VHL-deficient RCC
cell lines, it was recently shown that HIF-1ainhibits mitochondrial
respiration by activating MXI-1 transcription, which encodes a c-
Myc repressor [23]. C-Myc inhibition leads to down-regulation of
PCG-1b, a PPARc-coactivator that has been implicated in
mitochondrial biogenesis [24]. We therefore studied the expression
and activity of other complexes of the respiratory chain. We found
an overall decrease in subunits of complexes I to IV in tumors
from SDH and VHL patients. Biochemical analyses showed a
reduction in enzyme activities affecting the cytochrome c oxidase
(COX; complex IV) and, also, but to a much lesser extent, quinol
cytochrome c reductase (complex III). Again, such defects were not
observed in tumors that retain the ability to degrade HIFs in
normoxia (i.e. RET and NF1 tumors). Using transcriptome
analysis, we confirmed these findings and showed that unsuper-
vised analysis of gene expression in the OXPHOS pathway
is highly efficient to classify patients depending on cancer-
predisposing gene. However, for genes that were significantly
Figure 4. Increased glycolysis in VHL-related PH/PGL. (A) Hexokinase-II protein is detected in all VHL PH/PGL but is hardly detectable in RET,
NF1 and SDH samples. (B) Lactate dehydrogenase is increased in tumors harboring a VHL mutation as compared to SDH, RET and NF1 tumors.
doi:10.1371/journal.pone.0007094.g004
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expression were subtle, suggesting that regulation of mitochondrial
respiration principally occurred at the post-traductional level. We
performed MXI-1 and c-Myc immunohistochemistry (data not
shown) and analyzed MXI-1 and PGC1-b mRNA expression by
microarray, but such experiments led to negative results. There
was no difference in their respective expression in the different
types of hereditary PH/PGL, suggesting that the crosstalk between
HIF and c-Myc pathways described in RCC or lymphoma cell
lines [23,25], was not implicated in the decreased mitochondrial
biogenesis observed in human PH/PGL tissues.
Interestingly, a recent study showed that HIF-1 tightly regulates
the expression of the COX4-1 and COX4-2 subunits and of the
LON mitochondrial protease, in such a way that conditions
stabilizing HIF-1 lead to a decreased COX activity, which was
interpreted by the authors as an optimization of respiration
Figure 5. Microarray analysis of oxidative phosphorylation in hereditary PH/PGL. (A) Unsupervised hierarchical clustering analysis of the
68 samples according to the expression of 200 genes. Expression profiles are shown as a heat map indicating high (red) and low (blue) expression
according to a log2-transformed scale. The higher bipartition allows to distinguish VHL (white) and SDH (grey) patients from RET and NF1 (black)
patients. (B) Principal component analysis of the 68 samples according to the expression of 200 genes. Three groups are focused on, corresponding
to the SDH (red), VHL (green) and RET/NF1 (blue) patients. PC1: principal component; PC2: principal component 2; PC3: principal component 3. (C)
Mean values for genes expression between SDH, VHL, RET and NF1 tumors. Data are means6SEM, represented as relative to NF1 expression values.
**p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0007094.g005
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on 68 inherited PH/PGL confirmed the observations made in vitro
in human tumor tissues. COX4-2 was drastically overexpressed in
pseudo-hypoxic PH/PGL as compared to RET and NF1 tumors,
while COX4-1 was decreased two-fold. These results provide a
possible molecular mechanism for the decrease in COX activity
observed in SDH and VHL tumors. The NDUFA4L2 transcript
was also strongly overexpressed in PH/PGL harboring SDH and
VHL mutations. Interestingly, this gene was identified as the first
gene up-regulated in a transcriptome analysis of hypoxic
neuroblastoma cells, another neural-crest derived tumor that
shares a number of features with PH/PGL [27]. NDUFA4L2
encodes a protein homologous to the NADH dehydrogenase
(ubiquinone) 1 alpha subcomplex 4, a subunit of mitochondrial
complex I. Although the function of this protein is unknown, one
could postulate that it may act as a COX4-1/COX4-2 switch,
Figure 6. Microarray analysis of glycolysis in hereditary PH/PGL. (A) Unsupervised hierarchical clustering analysis of the 68 samples
according to the expression of 38 genes. Expression profiles are shown as a heat map indicating high (red) and low (blue) expression according to a
log2-transformed scale. The different mutations are localized in three distinct clusters: SDH (grey), VHL (white) and RET/NF1 (black). (B) Mean values
for genes expression between SDH, VHL, RET and NF1 tumors. Data are means6SEM, represented as relative to NF1 expression values. **p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0007094.g006
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observations demonstrate a reduced electron transport in some
inherited PH/PGL and suggest that activation of the hypoxic
response may be directly involved in the decreased mitochondrial
respiration in these tumors.
One of the first described functions of the HIF pathway is
activation of glycolysis; HIF-1a up-regulates the expression of most
glycolytic enzymes and the glucose transporters GLUT1 and 3. As
for vascularization and reduction in electron transport complexes,
we thus expected to observe more active glycolysis in SDH and
VHL PH/PGL than in RET and NF1 tumors. Most surprisingly,
both expression of hexokinase II and the activity of lactate
dehydrogenase were high in VHL patients, but not in SDH
specimens. Transcriptome analysis confirmed the specific activa-
tion of glycolysis in VHL PH/PGL, indicating that such analysis
was a powerful tool to discriminate VHL from non-VHL inherited
PH/PGL. It is likely that in the case of an SDH defect, the cells
might cope more easily with decreased ATP production by the
mitochondria, as most of the respiratory chain will still be
functional, and several metabolic shunts are potentially able to
provide electrons and generate a membrane potential sufficient to
generate normal levels of ATP. These observations were however
unexpected, notably because positron emission tomography with
2-[(18)F]-fluoro-2-deoxy-D-glucose ([(18)F]-FDG PET) tracing
glucose uptake was recently shown to be particularly sensitive
for the evaluation of bone metastases in patients harboring SDHB
mutations [28]. However, it is worth noting that, if whole
glycolysis was not enhanced in SDH patients (as compared to
RET or NF1), this subset of tumors did present a 4-fold increase in
GLUT3 mRNA expression, as assessed by microarray. This
augmentation would be sufficient to explain the high sensitivity of
SDH tumors to [(18)F]-FDG PET and confirms that such
approach is indeed relevant for the clinical evaluation of SDHB-
related patients. The overexpression of mRNA encoding GLUT1
(7-fold), GLUT3 (4-fold) and HXK-II (15-fold) in VHL PH/PGL
suggests that sensitivity for [(18)F]-FDG PET should be evaluated
in these patients, where it is expected to be highly effective.
One possible explanation for the discrepancy observed between
VHL and SDH tumors for the rest of the glycolytic pathway arises
Table 1. Expression of p53 and TIGAR in inherited PH/PGL
evaluated by immunohistochemistry.
Patient nu Gene mutated TIGAR p53
P11 RET + 2
P20 RET 22
P12 NF1 ++
P19 NF1 ++
P9 SDHD ++
P10 SDHB ++
P22 SDHB ++
P23 SDHB 2 +
P24 SDHB 2 +
P25 SDHB ++
P26 SDHD ++
P27 SDHC ++
P6 VHL 22
P7 VHL 2 +
P14 VHL 22
P16 VHL 22
P18 VHL 22
P3 VHL 22
P4 VHL 22
P5 VHL ++
TIGAR is absent from 7 of 8 VHL tumor tissues, but was detected in 9 of 12 RET,
NF1 and SDH tumors.
doi:10.1371/journal.pone.0007094.t001
Figure 7. Representative expression of p53 and TIGAR in PH/PGL. Immunohistochemistry revealed a mild to strong nuclear p53 labeling, and
the cystoplasmic expression of TIGAR in the majority of RET, NF1 and SDH tumors. Such labeling was only detected in 2 out of 9 VHL tumor tissues
(data not shown). In most VHL PH/PGL p53 protein and its target TIGAR were hardly detectable. Calibration bar: 50 mm.
doi:10.1371/journal.pone.0007094.g007
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expression of different target genes: HIF-1a is the transcription
factor involved in hypoxic induction of glycolysis but HIF-2a does
not seem to participate in this process [29]. Pollard et al. recently
reported the immunohistological analysis of HIFs factors in VHL
and SDH-related PH/PGL [30]. They described a relatively
higher expression of HIF-2a than HIF-1a in VHL tumors and a
reverse pattern in SDH tumors. Surprisingly, in our subset of
tumors, we observed high HIF-2a and low HIF-1a expression in
both SDH and VHL PH/PGL. The reason for this discrepancy
remains to be addressed and may be dependant on patients or,
although unlikely, on experimental conditions. On the other hand,
the predominance of HIF-2a is supported by previous observa-
tions performed in fetal paraganglia and neuroblastoma [31–33]
and by its upregulation at mRNA level in both VHL and SDH
PH/PGL. It could explain the absence of hypoxia-mediated
activation of the glycolytic response in these tumors. It thus
appears that the stimulation of glycolysis in VHL-PH/PGL is not
fully mediated by activation of the HIF pathway, but also depends
on an additional function of pVHL.
Recently, Roe et al. identified p53 as a new and unexpected
target of pVHL [20]. Unlike its activity on HIF proteins, VHL
binding to p53 suppresses Mdm2-mediated ubiquitination and
nuclear export and thereby leads to p53 stabilization. pVHL also
binds ATM and p300 to favor their stabilizing and activating
properties on p53. Loss of p53 has recently been associated with
mitochondrial and glycolytic metabolism. It can physically localize
to mitochondria where it causes mitochondrial DNA depletion
and altered reactive oxygen species homeostasis [34]. As a nuclear
transcription factor, it activates the expression of SCO2 [35] and
TIGAR [21], respectively implicated in the COX multimeric
protein complex assembly required for OXPHOS and in
inhibition of glycolysis. It therefore seemed plausible that p53-
dependant loss of TIGAR in VHL-mutated samples may explain
the activation of glycolysis specifically observed in these tissues. In
normal cells, nuclear p53 expression is usually below the detection
level of immunohistochemistry. Mutant p53, because of its longer
half-life can result in positive nuclear immunostaining. In the
present study, we were unable to detect p53 in PH/PGL samples
using a standard immunohistochemistry protocol. This observa-
tion is in accordance with most reported studies that showed very
little p53 mutations in benign PH/PGL [36–38]. However, using
tyramide signal amplification, we were able to reveal p53
expression in tumor tissues. We confirmed that TIGAR protein
was absent from 7/8 VHL-PH/PGL samples analyzed, but was
present in 9/12 non-VHL samples. These observations are the
first in situ demonstration of the link between VHL inactivation
and loss of the p53-TIGAR pathway in a human tumor. They
provide a pertinent explanation for the specific activation of
glycolysis in VHL-related PH/PGL.
In conclusion, our data establish the occurrence of a Warburg
effect specifically in PH/PGL harboring a VHL germ-line
mutation. Analysis of the underlying mechanism suggests that this
phenomenon depends on the activation of the pseudo-hypoxic
pathway — most probably mediated by the abnormal stabilization
of HIF-2a following VHL inactivation — and the loss of the p53/
TIGAR pathway. Together, these phenomena concur to the
observed decreased electron transport and increased glycolysis. In
SDH tumors, where p53 loss is not expected nor detected,
activation of whole glycolysis was not observed. Finally, in RET
and NF1 tumors, which are neither related to an activation of the
HIF pathway nor to a loss of p53, we did not observe any of the
metabolic or angiogenic inductions discernible in VHL tumors.
These results thus provide a direct insight into the mechanisms
underlying tumorigenesis in VHL-related PH/PGL and their links
with metabolic disorders.
Materials and Methods
Patients
We first analyzed 26 tumors collected by the COMETE
network from 25 patients (11 men, 14 women) operated on
between 1994 and 2005, in two tertiary referral centers in Paris:
the Hypertension Unit in Ho ˆpital Europe ´en Georges Pompidou
and the Department of Endocrinology in Ho ˆpital Cochin. Twenty
were pheochromocytomas and 6 were functional extra-adrenal
paragangliomas. The procedures used for PH/PGL diagnosis and
genetic testing were in accordance with institutional guidelines and
have been described previously [10,39]. The associated syndromic
lesions and the family history of each case are described in Table 2.
Two patients had a NF1 phenotype. The genetic testing identified
a germ-line RET mutation in three patients, an SDHB mutation in
five patients, an SDHD mutation in two patients, an SDHC
mutation in one patient and a VHL missense mutation in 12
patients. A large deletion in VHL from exon 1 to exon 3 was
detected in one patient by the QMPSF method [39]. For each
patient, we obtained two or three frozen samples and two paraffin-
embedded specimens prepared for routine pathological analyses.
For microarray studies, 42 additional patients with hereditary
PH/PGL were recruited for a total of 68 tumors studied (see
Table 3 for clinical characteristics of patients).
Ethics Statement
Informed signed consent for germline and somatic DNA
analysis was obtained from each patient recruited by the
COMETE network, and the study was formally approved by an
institutional review board (CPP Paris-Cochin).
Immunohistochemistry
Paraffin blocks were cut and sections (6-micrometers thick) were
mounted on Superfrost plus slides and used for immunohistochemistry
as previously described [31]. The protocol involved a biotinylated
secondary antibody (Vector Laboratories), an avidin-biotin-peroxidase
complex (Vectastain ABC Elite; Vector Laboratories) and diamino-
benzidin (Vector Laboratories) or Histogreen (Abcys) as chromogens
for the peroxidase activity. Anti b o d i e sw e r ea sf o l l o w s :H I F - 1 a
(H1alpha67, abcam, 1/500), HIF-2a (ab199, abcam, 1/1000), CD34
(Clone QBEND 10, Immunotech, 1/100), a-actin (#M0851, Dako,
1/1000), SDHB (HPA002868, Sigma-Aldrich, 1/500), Glut1 (Labvi-
sion, 1/200), p53 (Ab-8, Neomarkers 1/1000), TIGAR (abcam, 1/
200). p53 expression was revealed using the Tyramide Signal
Amplification (TSA) System (Perkin Elmer). Heat-mediated antigen
retrieval was performed for p53, Glut1, SDHB and TIGAR (10 mM
citrate buffer, pH 6, 15 min), and for HIF-1a and HIF-2a (Tris
1 0 0m M ,E D T A1m M ,0 , 0 5 %T w e e n ,p H9 ,4 5m i n ) .
Quantification of Vascular Density
Vascular density was measured on sections after CD34
immunostaining on the two independent samples obtained from
each patient. For each sample, total blood vessels were counted in
eight randomly chosen fields of 0.125 mm
2. For one patient (P6),
vascular density could not be evaluated because of an anarchic
vascular architecture.
Western Blotting
Frozen tissues were lysed in protein extraction buffer (25 mM
Tris, 100 mM NaCl, 0.5% NP40, 0.5% deoxycholic acid, 5 mM
EDTA, protease inhibitor cocktail (Sigma)).
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denaturing gels and transferred to either PVDF (Immobilon-P,
Millipore) for SDHB, SDHA and OXPHOS experiments or
nitrocellulose membranes (Hybond-ECL, Amersham Biosciences)
for p53 and HXK-II experiments. Ponceau staining confirmed
equivalent loading of each sample and membranes were then
blocked in 5% milk in TBST buffer, and probed with the primary
antibody.
Table 2. Clinical features of the patients studied.
Tumor
ID
Tumor
type
Hereditary
PH/PGL type Gene Mutation Sex
Age at
surgery
Tumor
size
(mm) Clinical characteristics Familial characteristics
P11 PH MEN2 RET A883F F 57 25 bilateral PH, MTC, marfanoid
habitus
P20 PH MEN2 RET C634R F 29 32 bilateral PH, MTC, MEN-2
family’s history
P12 PH neurofibromatosis
type 1
NF1 ND F 32 25 unique PH, ‘‘cafe ´-au-lait’’ spots,
Lisch nodules, scoliosis
P19 PH neurofibromatosis
type 1
NF1 ND F 32 50 unique PH, ‘‘cafe ´-au-lait’’ spots,
Lish nodules, neurofibroma
P21 PH neurofibromatosis
type 1
NF1 ND F 39 35 unique PH, ‘‘cafe ´-au-lait’’ spots,
Lish nodules
P9 EA FPGL hereditary
paraganglioma
SDHD R22X M 61 22 EA abdominal and bilateral
carotid PGL
P10 EA FPGL hereditary
paraganglioma
SDHB L207fs M 37 70 EA bladder PGL
P22 PH hereditary
paraganglioma
SDHB P56TyrfsX5 F 20 52 unique PH
P23 PH hereditary
paraganglioma
SDHB C253Y F 21 110 unique PH
P24 EA PGL hereditary
paraganglioma
SDHB F238SerfsX10 F 10 40 unique PGL
P25 PH hereditary
paraganglioma
SDHB R46G F 31 35 Unique PH
P26 EA PGL hereditary
paraganglioma
SDHD R22X M 32 35 Thoracic PGL, carotid PGL Father: bilateral carotid PGL;
brother: bilateral neck PGL
P27 EA PGL hereditary
paraganglioma
SDHC del exon 2 F 16 45 unique PGL
P1 PH von Hippel Lindau VHL Complete
deletion
M 32 30 unique PH, cerebellar and
bulbar HB
P2 PH von Hippel Lindau VHL S80I M 33 30 bilateral PH, retinal and
cerebellar HB, pancreatic kyst
P8/16 EA FPGL von Hippel Lindau VHL R161Q F 24 30 multiple EA abdominal PGL,
bilateral PH, renal kyst
P6 PH von Hippel Lindau VHL R167Q M 26 55 unilateral PH, retinal and
cerebellar HB, renal cancer
P7 PH von Hippel Lindau VHL L178P M 15 30 bilateral PH, carotid PGL P17’s cousin; uncle: bilateral PH,
renal cancers, bulbar HB
P14 PH von Hippel Lindau VHL Y98H F 29 30 bilateral PH P18’s daughter; aunt : unique PH,
cervical and thoracic PGL
P17 PH von Hippel Lindau VHL L178P M 13 50 bilateral PH P7’s cousin; father : bilateral PH,
renal cancers, bulbar HB
P18 PH von Hippel Lindau VHL Y98H M 51 30 unique PH, retinal HB, renal
cancer
P14’s father; sister : unique PH,
cervical and thoracic PGL
P3 PH von Hippel Lindau VHL Y156C M 18 30 unique PH, no renal cancer,
no HB
mother : unique PH, no renal
cancer, no HB
P4 EA FPGL von Hippel Lindau VHL Y156C M 20 25 EA abdominal PGL, no renal
cancer, no HB
mother: bilateral PH, vagal PGL,
no renal cancer, no HB
P5 PH von Hippel Lindau VHL P97L F 17 30 unique PH, no renal cancer,
no HB
brother : bilateral PH, no renal
cancer, no HB
P13 PH von Hippel Lindau VHL Y156H F 65 40 bilateral PH, multiple EA PGL,
no HB, no renal cancer
PH/PGL: pheochromocytoma/paraganglioma; EA FPGL: extra-adrenal functional paraganglioma; MTC: medullary thyroid carcinoma; HB: hemangioblastoma
doi:10.1371/journal.pone.0007094.t002
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SDHB (Molecular Probes, 1/1000), Oxphos complexes kit
(MitoSciences, 1/200), SDHA (Molecular Probes, 1/1000),
PDK-1 (#KAP-PK112, Stressgen, 1/2000), HXK-II (C-14, sc-
6521, Santa Cruz Biotechnology, 1/200), p53 (Ab-8, Neomarkers
1/400) and b-Actin (Clone AC-74, Sigma-Aldrich, 1/5000). The
membranes were then incubated with horseradish peroxidase-
linked secondary antibodies (Amersham Biosciences, 1/5000), and
bound antibodies were visualized using ECL Plus reagent
(Amersham Biosciences).
Assessment of Mitochondrial Respiratory Chain Function
and Enzyme Assay
Activities of cytochrome c oxidase (COX; complex IV),
succinate cytochrome c reductase (SCCR; complexes II+III),
quinol cytochrome c reductase (QCCR; complex III) and lactate
dehydrogenase were measured spectrophotometrically using a
pseudo dual-wavelength Cary 50 spectrophotometer (Varian,
Melbourne, Australia) [40].
Microarray
Tumor samples (20 to 30 mg) were powdered under liquid
nitrogen. RNAs were extracted using RNeasy mini kit (Qiagen).
Aliquots of the RNA were analyzed by electrophoresis on a
Bioanalyser 2100 (Agilent Technologies) and quantified using
Nano Drop ND-1000 (Labtech). Stringent criteria for RNA
quality were applied to rule out degradation, especially a 28 s/18 s
ratio above 1.5. Microarray analyses were performed using 3 mgo f
total RNA of each sample as starting material and 10 mg cRNA
per hybridization (GeneChip Fluidics Station 400; Affymetrix,
Santa Clara, CA). The total RNA were amplified and labeled
following the manufacturer’s one-cycle target labeling protocol
(http://www.affymetrix.com). The labeled cDNA were then
hybridized to HG-U133 Plus 2.0 Affymetrix GeneChip arrays
(Affymetrix). The chips were scanned with a GCOS 1.4.
Statistical Analysis
Statistical analyses were performed using the Stat View software
(SAS Institute Inc.). Differences were evaluated by ANOVA
Bonferroni Test. A p value ,0.05 was considered statistically
significant. Microarray analyses were performed with R system
software (http://www.R-project.org, V2.3.0) including packages
of Bioconductor [41]. Raw feature data from Affymetrix HG-
U133 Plus 2.0 GeneChip
TM microarrays were normalized using
robust multi-array average (RMA) method (Bioconductor package
affy) [42]. We used Welch’s t-tests to identify genes differentially
expressed between groups of samples (R package stats). Clustering
were performed using Ward linkage and (1-Pearson coefficient of
correlation) as inter-individual distance (R package cluster).
Principal component analysis was performed using the function
prcomp (R package stats).
Genes from the KEGG pathway ‘Oxidative phosphorylation’
(hsa00190) were obtained from (http://www.genome.ad.jp/kegg/
kegg2.html). The glycolysis pathway genes comprised glucose
transporters, glycolytic enzymes, lactate dehydohygenase and
lactate transporter, as well as TIGAR.
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